Antiplatelet Therapy Reversal for Surgical Professionals

CME

STS 2025: When Every Second Counts: The Latest Data and Expert Guidance on Antiplatelet Therapy Reversal for Surgical Professionals

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 10, 2025

Expiration: February 09, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following P2Y12 inhibitors acts as a reversal inhibitor on platelet receptors?

2.

A 68-yr-old man with a history of CAD on ticagrelor for ACS presents to the ED. He requires urgent CABG due to acute clinical decompensation. What is the most appropriate option to manage bleeding risk in this patient?

3.

The primary finding of the interim results from the REVERSE-IT trial showed that bentracimab: